Updating results

Provider information

Provider grid Details of the Content Resources and services offered by appointed Providers under the NICE Electronic and Print Content Framework....

Published November 2019 Last updated November 2019

DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

We’ve temporarily withdrawn this medtech innovation briefing to correct factual errors in the text.

Medtech innovation briefing Published November 2019

Preliminary Independent Model Advice (PRIMA)

Advice on improving the quality of economic models

Published November 2019 Last updated November 2019

Scholars

Scholarships are one year opportunities to improve quality of care and contribute to your professional development

Published November 2019 Last updated November 2019

Respiratory conditions

Everything NICE has said on respiratory conditions in an interactive flowchart

NICE Pathway Published June 2015 Last updated October 2019

Generalised anxiety disorder

Everything NICE has said on managing generalised anxiety disorder in adults in primary, secondary and community care in an interactive flowchart

NICE Pathway Published March 2012 Last updated October 2019

Pressure ulcers

Everything NICE has said on preventing and managing pressure ulcers in all age groups in primary care and community settings in an interactive flowchart

NICE Pathway Published January 2012 Last updated October 2019

NICE guidelines

NICE guidelines are evidence-based recommendations for health and care in England.

Published October 2019 Last updated October 2019

Committee B members

Find out more about the NICE technology appraisal advisory committee B members and their registered interests

Published October 2019 Last updated October 2019

Abortion care

Everything NICE has said on abortion care in an interactive flowchart.

NICE Pathway Published September 2019 Last updated October 2019

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

History of NICE

1999 Creation of NICE The National Institute for Clinical Excellence became a legal entity in April. Our aim was to create consistent guidelines

Published October 2019 Last updated October 2019

Blackwells

Provider name: Blackwells Lot details Lot 2 - Electronic Books Lot 2 Agent - Print Books, Electronic Books Provider helpdesk

Published October 2019 Last updated October 2019

How giving a committee voice to people with a learning disability added value to NICE quality standards

Chris Bird, Quality Standards Programme Manager, tells us how NICE developed the latest learning disability quality standards

News Published October 2019 Last updated October 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Diagnostic technologies stakeholder registration

Who can become a registered stakeholder? Registration is open to anyone with an interest in the topic who is one of the following: The company that

Published October 2019 Last updated October 2019

Antimicrobial prescribing guidelines

Evidence-based antimicrobial prescribing guidance for primary and secondary care with a focus on bacterial infection and antibiotic use.

Published October 2019 Last updated October 2019

Using our guidance

Support for voluntary and community sector organisations using NICE guidance

Published October 2019 Last updated October 2019

Non-Hodgkin's lymphoma

Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

NICE Pathway Published July 2016 Last updated October 2019

Our committees

Find out more about being on a committee at NICE.

Published October 2019 Last updated October 2019

How GPs help develop our guidance

How a range of GPs can benefit from working with us on our committees to develop our guidance.

Published October 2019 Last updated October 2019

NICE impact: sexual health

How NICE recommendations are being used to improve sexual health

Published October 2019 Last updated October 2019

Multi-disciplinary pathway development for individual with dementia and a learning disability

A multi-disciplinary working group was set up to look at how the NICE guidance for dementia should be applied to adults with a learning disability.

Shared learning Published October 2008

Enhancing the Quality of Heart Failure Care

Shared learning Published January 2017

How effective and cost effective are education-based alcohol interventions targeted at children and young people aged 11 to 25 with SEND who are thought to be vulnerable to alcohol misuse?

Recommendation ID NG135/4 Question How effective and cost effective are education-based alcohol interventions targeted at children and young

Research recommendation Published October 2019

How effective and cost effective are individual, compared with group, education-based interventions for children and young people aged 11 to 18 in full-time education who are thought to be vulnerable to alcohol misuse?

Recommendation ID NG135/2 Question How effective and cost effective are individual, compared with group, education-based interventions for

Research recommendation Published October 2019

What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates?

Recommendation ID NG130/2 Question What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate

Research recommendation Published October 2019

What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?

Recommendation ID NG130/3 Question What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition

Research recommendation Published October 2019

How effective and cost effective are universal, education-based alcohol interventions for children and young people aged 11 to 25 with SEND?

Recommendation ID NG135/3 Question How effective and cost effective are universal, education-based alcohol interventions for children and

Research recommendation Published October 2019

What components of alcohol education delivery contribute to its effectiveness for children and young people aged 11 to 18 in full-time education, and those with special educational needs and disabilities (SEND) up to the age of 25?

Recommendation ID NG135/1 Question What components of alcohol education delivery contribute to its effectiveness for children and young

Research recommendation Published October 2019

The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices in primary care for people with signs or symptoms of atrial fibrillation, and an irregular pulse, increases the number of people with atrial fibrillation (including paroxysmal) detected, ompared with current practice (that is, a 12‑lead ECG done later). The committee considered the feasibility of collecting data to see if using the lead‑I ECG devices increased the detection of atrial fibrillation that would be missed if only 12‑lead ECGs done later were available. It noted that even if a lead‑I ECG is used and atrial fibrillation is detected, a subsequent 12‑lead ECG would still be done to check for structural cardiac abnormalities and inform further management decisions. The committee concluded that practices using lead‑I ECG devices could determine the number of additional cases of atrial fibrillation detected by the devices. This can be done by identifying people with a confirmed positive lead‑I ECG for atrial fibrillation who subsequently had a 12‑lead ECG that was negative because the atrial fibrillation had stopped. The committee also considered that data collected on the time between the initial lead‑I ECG and the subsequent 12‑lead ECG would be useful.

Recommendation ID DG35/1 Question The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices

Research recommendation Published October 2019

What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the post-surgical period of Crohn's disease?

Recommendation ID NG129/1 Question What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the

Research recommendation Published October 2019

What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis?

Recommendation ID NG130/4 Question What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction

Research recommendation Published October 2019

What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis?

Recommendation ID NG130/5 Question What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone

Research recommendation Published October 2019

What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

Recommendation ID NG130/6 Question What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab

Research recommendation Published October 2019